logo
welcome
Reuters

Reuters

Lilly's weight-loss drug Zepbound wins US FDA approval for sleep apnea

Reuters
Summary
Nutrition label

77% Informative

U.S. Food and Drug Administration approves Eli Lilly's weight-loss treatment, Zepbound , for obstructive sleep apnea.

It is the first drug greenlighted to directly treat patients with the common sleeping disorder.

Sleep apnea patients stop breathing briefly while sleeping, disturbing the sleep cycle and causing long-term complications.

VR Score

85

Informative language

91

Neutral language

50

Article tone

formal

Language

English

Language complexity

58

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

short-lived

External references

no external sources

Source diversity

no sources

Affiliate links

no affiliate links